Insulin aspart: An evidence-based medicine review

Clinical Drug Investigation

Volumn 24, Issue 12, 2004, Pages 695-717

  Haycox, Alan ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART;

BIOSIS; COCHRANE LIBRARY; CONTINUOUS INFUSION; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EMBASE; EVIDENCE BASED MEDICINE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

EID: 10844234946     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424120-00002     Document Type: Review

References (113)

1. World Health Organization. Global strategy on diet, physical activity and health: chronic disease information sheet: Diabetes, 2003 [online]. Available from URL: http://www.who.int/ dietphysicalactivity/publications/facts/diabetes/ en/print.html [Accessed 2004 Aug 10]
2. American Diabetes Association National Diabetes Fact Sheet 2002a. Available from URL: http://www.diabetes.org [Accessed 2004 Feb 26]
3. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-32
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53
6. Chapman TM. Insulin aspart. Drags 2002; 62: 1945-81
7. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001; 40: 641-59
8. Keckley PH. The role of evidence-based medicine in disease management. Dis Manage Health Outcomes 2003; 11: 429-37
9. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence-based medicine: what it is and what it isn't. BMJ 1996; 312: 71-2
10. Canadian Task Force on the Periodic Health Examination: The Periodic health examination. CMAJ 1979; 121: 1193-1254
11. Oxford Centre for Evidence-based Medicine 2004. Frequently asked questions. Available from URL: http://www.cebm.net/levels_faq.asp [Accessed 2004 Mar 30]
12. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25 Suppl. 1: S33-49
13. Boehm BO, Home PD, Bott U, et al. Premixed insulin aspart 30: Control and convenience in type 1 and type 2 diabetes. Diabetologia 2000; 43 Suppl. 1: A200
14. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs premised human insulin 30.70 twice daily: a randomised trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19 (5): 393-9
15. Home P, Boehm BO, Bott U, et al. Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: a randomized 12-week comparison [abstract]. Diabetes Res Clin Pract 2000; 50 Suppl. 1: S37
16. Boehm B, Home P, Kamp N, et al. Biphasic insulin aspart and biphasic human insulin compared in type 2 diabetic subjects [abstract]. Diabetologia 2001; 44 Suppl. 1: A210
17. Hermansen K, Vaaler S, Madsbad S, et al. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. Metabolism 2002; 51 (7): 896-900
18. Hermansen K, Vaaler S, Madsbad S, et al. Biphasic insulin aspart 30 improves postprandial glycemic control [abstract]. Diabetes 2001; 50 Suppl. 2: A95
19. McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24 (4): 530-9
20. Christiansen JS. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 446-54
21. Kapitza C, Nosek L, Lindholm A, et al. Biphasic insulin aspart provides good metabolic control even when injected postprandially [abstract]. Diabetes 2001; 50 Suppl. 2: A119
22. Kapitza C, Nosek L, Lindholm A, et al. Codony Silva GHTC. Postprandial dosing of the "lowmix" biphasic insulin aspart [abstract]. Diabetologia 2001; 44 Suppl. 1: A211
23. Kapitza C, Rave K, Ostrowski K, et al. Reduced postprandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a meal. Diabetic Med 2004; 21: 497-501
24. Thivolet C, Clements M, Ligthelm RJ, et al. High-mix regimen of biphasic insulin aspart improves glycaemic control in patients with diabetes [abstr]. Diabetologia 2002; 45 Suppl. 2: A254
25. Christiansen JS, Ejskjaer N, Rasmussen M, et al. Testing the concept of administering thrice daily premixed insulin aspart in type 2 diabetes [abstract]. Diabetes Res Clin Pract Suppl 2000; 50 Suppl. 1: S67
26. Ejskjaer N, Rasmussen M, Kamp N, et al. A randomised, crossover, double-blind trial testing the concept of administering premixed insulin aspart thrice daily in patients with type 2 diabetes. Diabetes 2001; 50 Suppl. 2: A434
27. Ejskjaer N, Rasmussen M, Kamp N, et al. Comparison of thrice daily 'high' vs 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 438-45
28. Amiel S, Home PD, Jacobsen JL, et al. Insulin aspart safe for long-term treatment [abstract]. Diabetologia 2001; 44 Suppl. 1: A209
29. Bode BW, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous infusion therapy in patients with type 1 diabetes. Diabetes Care 2001; 24 (1): 69-72
30. Bode B. Efficacy and safety of insulin aspart compared to buffered human insulin by continuous SC insulin infusion [abstract]. Diabetologia 2000; 43 Suppl. 1: A200
31. Bode B, Strange P, McCulloch K. Efficacy and safety of insulin aspart compared to buffered human insulin by continuous SC insulin infusion [abstract]. Diabetes Res Clin Pract Suppl 2000; 50 Suppl. 1: S223
32. Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000; 17 (5): 371-5
33. Brunner GA, Hirschberger S, Sendlhofer G, et al. Prandial glycemia with subcutaneous injection of insulin aspart after the meal in type 1 diabetic patients. Diabetes 1999; 48 Suppl. 1: A98-9
34. Colagiuri S, Heller S, Vaaler S, et al. Insulin aspart reduces the frequency of nocturnal hypoglycaemia in patients with type 1 diabetes [abstract]. Diabetologia 2001; 44 Suppl. 1: A210
35. Heller S, Colagiuri S, Vaaler S, et al. Reduced hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in type 1 diabetic patients [abstract]. Diabetes 2001; 50 Suppl. 2: A137
36. DeVries JH, Lindholm A, Heine RJ, et al. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in type 1 diabetes [abstract]. Diabetologia 2001; 44 Suppl. 1: A209
37. DeVries JH, Lindholm A, Jacobsen JL, et al. Tri-Continental Insulin Aspart Study Group. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1 diabetes. Diabet Med 2003; 20 (4); 312-8
38. Gallagher A, Home PD. The effect of insulin aspart on metabolic outcomes and albumin excretion in type 2 diabetes [abstract]. Diabetologia 2000; 43 Suppl. 1: A200
39. Gallagher A, Home PD. The effect of insulin aspart on postprandial metabolism and metabolic outcome in type 2 diabetes [abstract]. Diabetologia 2001; 44 Suppl. 1: A209
40. Gallagher A, Home PD. The effect of insulin aspart on postprandial metabolism and lipid profile in type 2 diabetes. Diabetologia 2002; 45 Suppl. 2: A253-4
41. Gallagher A, Home PD. The effect of insulin aspart on metabolic outcome and markers of arterial risk in type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A435
42. Harris N, Robinson RTCE, Ireland RH, et al. Comparative effects of human soluble insulin and the new insulin analogue, insulin aspart upon ventricular repolarization [abstract]. Diabetes 1999; 48 Suppl. 1: A114
43. Heller S. Soluble insulin and the rapid-acting analogue insulin aspart have similar effects upon ventricular repolarization [abstract]. Diabetologia 1999; 42 Suppl. 1: A237
44. Robinson RT, Harris ND, Ireland RH, et al. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 2003 Jun; 52 (6): 1469-74
45. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicentre randomised double blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21 (11): 1904-9
46. Home PD, Lindholm A, Riis A, et al. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000; 17 (11): 762-70
47. Home PD, Lindholm A, Riis A. Insulin aspart improves long-term glycaemic control in type 1 diabetes: a randomized trial vs human insulin [abstr]. Diabetologia 1999; 42 Suppl. 1 : A17
48. Home PD, Lindholm A, Riis A. Improved long-term blood glucose control with insulin aspart versus human insulin in people with type 1 diabetes [abstract]. Diabetes 1999; 48 Suppl. 1: A358
49. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22 (5): 801-5
50. Lindholm A, McEwen J, Riis A. Significantly improved postprandial glycaemic control with the novel rapid-acting insulin aspart [abstract]. Diabetologia 1998; 41 Suppl. 1: A49
51. McGill J, Raskin P, Kilo C, et al. Human insulin analog, insulin aspart, is a mealtime insulin comparable to human insulin in type 2 diabetes [abstract]. Diabetologia 1999; 42 Suppl. 1: A238
52. Raskin P, McGill J, Kilo C, et al. Human insulin analog (insulin aspart, IAsp) is comparable to human insulin (HI) in type 2 diabetes [abstract]. Diabetes 1999; 48 Suppl. 1: A355
53. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23 (5): 583-8
54. Hoogwerf B, Raskin P, Jovanovic L, et al. Insulin aspart: a mealtime alternative to soluble human insulin in type 1 diabetes [abstract]. Diabetologia 1999; 42 Suppl. 1: A237
55. Raskin P, Jovanovic L, Guthrie RA, et al. Insulin aspart (IAsp) improves glycemic control compared to human insulin (HI) for patients with type 1 diabetes [abstract]. Diabetes 1999; 48 Suppl. 1: A115
56. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37 (1): 41-6
57. Rosenfalck AM, Thorsby P, Kjems L, et al. Effects of the rapid-acting insulin analogue Insulin Aspart on postprandial glycaemic excursions compared to human soluble insulin Actrapid given immediately or 30 minutes before a meal in insulin treated type 2 diabetes patients [abstract]. Diabetes 1999; 48 Suppl. 1: A116
58. Thorsby P, Rosenfalck AM, Kjems L, et al. Effects of the rapid-acting insulin analogue Insulin Aspart on postprandial glycaemic excursions in type 2 diabetes [abstract]. Diabetologia 1999; 42 Suppl. 1: A17
59. Tamas G, Marre M, Astorga R, et al. Insulin Aspart Study. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001; 54 (2): 105-14
60. Bretzel RG, Medding J, Hirschberger S, et al. Insulin aspart efficacy and safety compared to human soluble insulin and human premix insulin (30/70) in patients with type 2 diabetes mellitus [abstract]. Diabetologia 2001; 44 Suppl. 1: A209
61. Bretzel RG, Arnolds S, Medding J, et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004; 27: 1023-7
62. Frier BM, Ewing FM, Lindholm A, et al. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in type 1 diabetes. Diabetes Metab Res Rev 2000; 16 (4): 262-8
63. Umpierrez G, Latif K, Cuervo R, et al. Subcutaneous aspart insulin: a safe and cost effective treatment of diabetic ketoacidosis [abstract]. Diabetes 2003 Jun; 52 Suppl. 1: 136
64. Nosek L, Heinemann L, Kaiser M, et al. No increase in the duration of action with rising doses of insulin aspart [abstract]. Diabetologia 2003 Aug; 46 Suppl. 2: 268
65. Nosek L, Heinemann L, Kaiser M, et al. No increase in the duration of action with rising doses of insulin aspart. Diabetes 2003 Jun; 52 Suppl. 1: 128-9
66. Perriello G, Avogaro A, Emanuele B, et al. Superior meal-time glucose control with insulin aspart (NovoLog) compared with human insulin in both normal-weight and overweight people with type 2 diabetes; a randomized, stratified, double-blind, crossover trial [abstract]. Diabetes 2002 Jun; 51 Suppl. 2: A111
67. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-9
68. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic controt compared with nph insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004 May; 27 (5): 1081-7
69. Lindholm A, Jensen LB, Home PD, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25 (5): 876-82
70. Yki-Yarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67
71. De Boer H. Prevention of weight gain in type 2 diabetes requiring insulin treatment. Diabetes Obes Metab 2004; 6: 114-9
72. Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellituset al. Diabet Med 2000; 17: 371-5
73. Bolt U, Ebrahim S, Hirschberger S, et al. Effect of the rapid acting insulin analogue Insulin Aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients [abstract]. Diabetes 1999; 48 Suppl. 1: A112
74. Bott U, Ebrahim S, Hirschberger S, et al. Effect of the insulin analogue insulin aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients. Diabetologia 1999; 42 Suppl. 1: A237
75. Bott U, Ebrahim S, Hirschberger S, et al. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003; 20 (8): 626-34
76. Mortensen HB, Lindholm A, Olsen BS, et al. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000; 159 (7): 483-8
77. Tsalikian E, Bright G. Insulin aspart in paediatric and adolescent patients with type 1 diabetes [abstract]. J Paediatr Endocrinol 2000; 13 Suppl. 4: 1218
78. Tsalikian E. Insulin aspart in paediatric and adolescent patients with type 1 diabetes. Diabetologia 2000; 43 Suppl. 1: A200
79. Tsalikian E, Mueller PG. Insulin aspart in paediatric and adolescent patients with type I diabetes [abstract]. Diabetes Res Clin Pract Suppl 2000; 50 Suppl. 1: S422
80. Tsalikian E, Mueller PG. Insulin aspart in paediatric patients with type I diabetes [abstract]. Paediatr Res 2000; 47: 140A
81. Mortensen H, Olsen B, Lindholm A. Pharmacokinetics of a rapid acting human insulin analogue, insulin aspart, in children and adolescents with type 1 diabetes [abstract]. Diabetes 1999; 48 Suppl. 1: A358
82. Olsen B, Lindholm A, Mortensen H, et al. Pharmacokinetics and pharmacodynamics of the rapid-acting analogue insulin aspart in pediatric/adolescent patients with type 1 diabetes [abstract]. Pediatr Res 2000; 47 (Pt 2): 136A
83. Olsen BS, Mortensen HB, Lindholm A. Age-dependent pharmacokinetics of human insulin and insulin aspart in children and adolescents with type 1 diabetes [abstract]. Horm Res 1999; 51 Suppl. 2: 92
84. Olsen B, Mortensen H, Lindholm A, et al. Age-dependent pharmacokinetics of human insulin and insulin aspart in young patients. Diabetologia 1999; 42 Suppl. 1: A236
85. Mortensen H, Kocova M, Bruckner I, et al. Comparison of biphasic insulin aspart and human insulin including biphasic human insulin in children with type 1 diabetes: a safety and efficacy trial [abstract]. Diabetes Metab 2003; 29: 4S227
86. Danne T, Aaman J, Schover E, et al. Preprandial versus postprandial insulin aspart treatment in type 1 diabetic children and adolescents. Diabetologia 2001; 44 Suppl. 1: A257
87. Danne T, Aman J, Scober E, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26: 2359-64
88. American Diabetes Association. type 2 diabetes in children and adolescents. Diabetes Care 2000; 23: 381-9
89. Raskin P, Bode B, Marks JB, et al. Insulin aspart (IAsp) is as effective in continuous subcutaneous insulin infusion as in multiple daily injections for patients with type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A128
90. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003; 26 (9): 2598-603
91. De Vries JH, Snoek FJ, Kostene PJ, et al. A randomised trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes patients with long standing poor glycemic control. Diabetes Care 2002; 25: 2074-80
92. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002; 25 (3): 439-44
93. Bode B, Weinstein R, Bell D, et al. Insulin aspart efficacy and safety compared to buffered regular insulin (velosulin®) and insulin lispro for continuous subcutaneous insulin infusion [abstract]. Diabetes 2001; 50 Suppl. 2: A106
94. Heise T, Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Des 2001; 7: 1303-25
95. Bolli GB. Rationale for using combinations of short-acting insulin analogue and NPH insulin at mealtime in the treatment of type I diabetes mellitus. J Pediatr Endocrinol Metab 1999; 12 Suppl. 3: 737-44
96. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999; 43 (2): 137-42
97. Colquitt J. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003; 20: 863-6
98. De Witt D, Hirsch IB. outpatient insulin therapy in type 1 and type 2 diabetes mellitus. Scientific Review. JAMA 2003; 289: 2254-64
99. Recognising the value of evidence-based medicine; summary prepared by Adis editors. PharmacoEconomics and Outcomes News 2000; 1 (252): 4
100. Raz I, Weinstein J, Hershkovits TA, et al. Add-on of insulin or a second oral agent? Evaluation of premixed insulin aspart in combination with repaglinide, glibenclamide, metformin and rosiglitazone [abstract]. Diabetologia 2002; 45 Suppl. 2: A263
101. Raz I, Mouritzen U, Vaz J, et al. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003; 25: 3109-23
102. Henriksen JE, Poulsen MK, Hother-Nielson O, et al. Triple therapy using metformin, rosiglitazone and insulin aspart is superior to NPH insulin twice daily in patients with type 2 diabetes [abstr]. Diabetologia 2002; 45 Suppl. 2: A264
103. Poulsen MK, Henriksen JE, Hother-Nielsen O, et al. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003; 26 (12): 3273-9
104. Kvapil M, Mikolajczyk-Swatko A, Ostergaard AH, et al. In patients with poorly controlled type 2 diabetes, biphasic insulin aspart 30 combined with metformin provides better glycaemic control than sulphonylurea/metformin combination. Diabetologia 2002; 45 Suppl. 2: A18
105. Kilo C. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003; 17: 307-13
106. Pettitt DJ, Ospina P, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetologia 2002; 45 Suppl. 2: A254-5
107. Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus [abstract]. Diabetes 2002; 51 Suppl. 2: A434
108. Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 2003; 26: 183-6
109. Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart: a safe alternative in insulin allergy [letter]. Diabetes Care 2001; 24 (11): 2000
110. Yasuda H, Nagata M, Moriyama H, et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care 2001; 24 (11): 2008-9
111. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev 2002; 18 Suppl. 3: 564-9
112. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2004
113. Oxford Centre for Evidence-based Medicine Levels of Evidence 2001. Available from URL: http://www.cebm.net/levels_of_evidence.asp [Accessed 2004 Feb 27]